Brief: Pila Pharma Completes 13-Week Safety Studies In Rats With No Adverse Signals In Dosing Phase

Pila Pharma AB

11/10/2022 12:07

Oct 11 (Reuters) - Pila Pharma AB  PILA.ST :
    * PILA PHARMA COMPLETES 13-WEEK SAFETY STUDIES IN RATS WITH
NO
ADVERSE SIGNALS DURING THE DOSING PHASE
    * 13-WEEK TOX PACKAGE IS DUE TO BE COMPLETED BY END OF 2022
    * ALL RESULTS OF "13-WEEK SAFETY PACKAGE" ARE EXPECTED IN
EARLY
2023

Source text for Eikon:  ID:nBQN508169 
Further company coverage:  PILA.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))